Drew Ranieri
Stock Analyst at Morgan Stanley
(1.23)
# 3,520
Out of 4,883 analysts
166
Total ratings
44.94%
Success rate
-12.53%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $4.25 | +41.18% | 4 | Mar 5, 2025 | |
| ATEC Alphatec Holdings | Assumes: Equal-Weight | $9.5 → $10 | $10.93 | -8.51% | 10 | Dec 2, 2024 | |
| GMED Globus Medical | Upgrades: Overweight | $83 → $100 | $55.97 | +78.67% | 12 | Dec 2, 2024 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $392.51 | +13.37% | 9 | Dec 2, 2024 | |
| SIBN SI-BONE | Maintains: Overweight | $21 → $19 | $17.96 | +5.79% | 15 | Aug 6, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $12.75 | +111.76% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $6.04 | +32.45% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $24.35 | -9.65% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $10.21 | -21.65% | 13 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $20.45 | +303.42% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $19.67 | +93.19% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $75.13 | +27.78% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $11.83 | +119.78% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $172.95 | +70.57% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $116.67 | +139.99% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $6.82 | -26.69% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $29.69 | +135.77% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $534.71 | -43.89% | 6 | Apr 25, 2022 |
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $4.25
Upside: +41.18%
Alphatec Holdings
Dec 2, 2024
Assumes: Equal-Weight
Price Target: $9.5 → $10
Current: $10.93
Upside: -8.51%
Globus Medical
Dec 2, 2024
Upgrades: Overweight
Price Target: $83 → $100
Current: $55.97
Upside: +78.67%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $392.51
Upside: +13.37%
SI-BONE
Aug 6, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $17.96
Upside: +5.79%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $12.75
Upside: +111.76%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $6.04
Upside: +32.45%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $24.35
Upside: -9.65%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $10.21
Upside: -21.65%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $20.45
Upside: +303.42%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $19.67
Upside: +93.19%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $75.13
Upside: +27.78%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $11.83
Upside: +119.78%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $172.95
Upside: +70.57%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $116.67
Upside: +139.99%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $6.82
Upside: -26.69%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $29.69
Upside: +135.77%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $534.71
Upside: -43.89%